Estrella Immunopharma Financials
| ESLA Stock | 1.23 0.15 10.87% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0564 | 0.0635 |
|
| |||||
| Current Ratio | 0.0489 | 24.6495 |
|
|
Investors should never underestimate Estrella Immunopharma's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Estrella Immunopharma's cash flow, debt, and profitability to make informed and accurate decisions about investing in Estrella Immunopharma.
Net Income |
|
Estrella | Select Account or Indicator |
Understanding current and past Estrella Immunopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Estrella Immunopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Estrella Immunopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Estrella Immunopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Estrella Immunopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Estrella Immunopharma's management manipulating its earnings.
Estrella Immunopharma Stock Summary
Estrella Immunopharma competes with Naked Wines, Tandem Diabetes, Monster Beverage, National Beverage, and Merit Medical. Estrella Immunopharma is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 89268A107 297584104 |
| Location | California; U.S.A |
| Business Address | 5858 Horton Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.estrellabio.com |
| Phone | 510 318 9098 |
Estrella Immunopharma Key Financial Ratios
| Return On Equity | -2.78 | ||||
| EBITDA | (1.57 M) | ||||
| Net Income | (7.31 M) | ||||
| Book Value Per Share | 0.12 X | ||||
| Market Capitalization | 51.99 M |
Estrella Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Estrella Immunopharma's current stock value. Our valuation model uses many indicators to compare Estrella Immunopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Estrella Immunopharma competition to find correlations between indicators driving Estrella Immunopharma's intrinsic value. More Info.Estrella Immunopharma is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At present, Estrella Immunopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Estrella Immunopharma's earnings, one of the primary drivers of an investment's value.Estrella Immunopharma Systematic Risk
Estrella Immunopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Estrella Immunopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Estrella Immunopharma correlated with the market. If Beta is less than 0 Estrella Immunopharma generally moves in the opposite direction as compared to the market. If Estrella Immunopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Estrella Immunopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Estrella Immunopharma is generally in the same direction as the market. If Beta > 1 Estrella Immunopharma moves generally in the same direction as, but more than the movement of the benchmark.
About Estrella Immunopharma Financials
What exactly are Estrella Immunopharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Estrella Immunopharma's income statement, its balance sheet, and the statement of cash flows. Potential Estrella Immunopharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Estrella Immunopharma investors may use each financial statement separately, they are all related. The changes in Estrella Immunopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Estrella Immunopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Estrella Immunopharma December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Estrella Immunopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Estrella Immunopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Estrella Immunopharma based on widely used predictive technical indicators. In general, we focus on analyzing Estrella Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Estrella Immunopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.66 | |||
| Information Ratio | 0.0843 | |||
| Maximum Drawdown | 41.75 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 10.34 |
Complementary Tools for Estrella Stock analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |